

Biointerfaces *International* 2020, University of Zurich, August 26, 2020
Parallel sessions about translational research and industrial applications

Preliminary Program

“Progress in cell-based in-vitro assays for drug development, substance toxicity testing, regenerative medicine – supporting 3R initiatives”

Session 1 08:30 - 09:10	Plenary Keynote Talk: Combining information on science and translational progress and future perspectives. Albert van den Berg , University of Twente, Enschede, NL
Session 2 09:10 – 10:10	The scientific & technological challenges in the development of tissue- and organ-like laboratory models to replace animal testing (3R concept). Chair: Markus Rottmar , Empa, CH <ul style="list-style-type: none">• Peter Loskill, µOrgano-Lab, University of Tübingen & Fraunhofer IGB, Stuttgart, DE• Tamer Mohamed, Aspect Biosystems, Vancouver, CA
Coffee Break	
Session 3 10:40 – 12:10	The translational challenges and current technical & institutional hurdles in the application of stem cell technology and tissue/organ-like laboratory models to replace animal testing (realizing 3R concept). Chair: Markus Rimann , TEDD, ZHAW, CH <ul style="list-style-type: none">• Adrian Roth, Roche, Basel, CH• Madhu Lal-Nag, U.S. Food and Drug Administration FDA, US• Catarina Brito, Universidade de Lisboa, PT
Lunch Break	
Session 4 13:30 – 14:30 Point – Counter Point Discussion “The long way from cell culture in the lab to drug testing using in vitro models to replace animal testing”.	Point – Counter Point Session: pro vs. con the statement “ Biosynthetic in vitro Organs/Organoids will not be validated to replace animal testing by regulatory agencies within the next 5 years ” Chair: David W. Grainger , University of Utah, US / Co-Chair: Michelle Grandin , Alfred E. Mann Institute, US <u>Pro/YES Role:</u> <ul style="list-style-type: none">• Bettina Ernst, Swiss Biotech Association, CH• Gerald Schwank, University of Zurich, CH <u>Contra/NO Role:</u> <ul style="list-style-type: none">• Reyk Horland, TissUse GmbH, DE• Rob Howes, AstraZeneca, SE
Session 5 14:30 – 15:10	Science-to-market: innovator showcases - pre-startups (contributed talks from academic research labs), Chair: Eliav Haskal , NCCR Bioinspired Materials
Coffee Break	
Session 6 15:40 – 16:40 Plenary Discussion: Emerging challenges and opportunities will be addressed from the perspective of a variety of stakeholders.	Plenary Discussion: Discussion Leader: Peter Wick , Empa, CH, Co-Discussion Leader: Sally McArthur , Swinburne University Melbourne, AU Swiss Institutional representatives from: <ul style="list-style-type: none">• Kathy Riklin, President of Swiss Competence Centre 3R (3RCC), CH• Silvia Frey, Managing Director, Animalfree Research, CH Industry representatives from: <ul style="list-style-type: none">• Fred Züllli, Mibelle AG, CH• Heinz Ruffner, Novartis AG, CH International Institutional representatives from : <ul style="list-style-type: none">• Madhu Lal-Nag, U.S. Food and Drug Administration, US
Session 7 16:40 – 17:30	Moving to the next step: innovator showcases - startups searching for partners to scale their business / technology (contributed talks from startup entrepreneurs), Chair: Jörg Güttinger , NTN Innovative Surfaces, CH

Speaker selection will be announced soon

Speaker selection will be announced soon